# Everolimus-eluting SYNERGY Stent Versus Biolimus-eluting Biomatrix NeoFlex Stent - SORT-OUT VIII

Study · id `cardio:ct-nct02093845` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02093845](<https://clinicaltrials.gov/study/NCT02093845>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02093845

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 2800 participants.

## Technical summary

Registry record NCT02093845. Randomized; no masking; primary purpose treatment. Start 2014-02-10 (actual); primary completion 2015-08-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 2800 participants (enrolled count; ClinicalTrials.gov record NCT02093845, source copy `cardio:ctgov-nct02093845-2017-04-25`, retrieved 2026-10-26)
- Started: 2014-02-10 (actual) (ClinicalTrials.gov record NCT02093845, source copy `cardio:ctgov-nct02093845-2017-04-25`, retrieved 2026-10-26)
- Primary completion: 2015-08-24 (actual) (ClinicalTrials.gov record NCT02093845, source copy `cardio:ctgov-nct02093845-2017-04-25`, retrieved 2026-10-26)
- Completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT02093845, source copy `cardio:ctgov-nct02093845-2017-04-25`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT02093845, source copy `cardio:ctgov-nct02093845-2017-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02093845-2017-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Everolimus-eluting SYNERGY Stent Versus Biolimus-eluting Biomatrix NeoFlex Stent - SORT-OUT VIII
- Acronym: SORT-OUT VIII
- Condition: Coronary Artery Disease
- Condition: Ischemic Heart Disease
- Intervention (Device): Biomatrix NeoFlex coronary stent
- Intervention (Device): SYNERGY stent
- Lead sponsor: Aarhus University Hospital Skejby
- Lead sponsor class: OTHER
- Collaborator: Boston Scientific Corporation
- Collaborator class: INDUSTRY
- Collaborator: Biosensors Europe SA
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Aarhus University Hospital Skejby (`cardio:org-aarhus-university-hospital-skejby`)
- Registry lists this organization as a collaborator: Boston Scientific (`cardio:boston-scientific`)
- Registry lists this organization as a collaborator: Biosensors Europe SA (`cardio:org-biosensors-europe-sa`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial) (`cardio:pubmed-30947936`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a3412306ab4c9d62984c332bbc41e2f69108a266621d07f8442773d690b29b9c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
